Lexaria Bioscience Advances GLP-1 Study with New Ethics Approval

Lexaria Bioscience ( (LEXX) ) has issued an announcement.

Lexaria Bioscience has received ethics board approval for the fifth study arm in its Phase 1b, 12-week chronic study GLP-1-H24-4 in Australia, allowing dosing to commence. This study, which includes two major GLP-1 drugs, semaglutide and tirzepatide, aims to explore the potential of Lexaria’s DehydraTECH technology to enhance drug performance through oral delivery. The approval marks a significant milestone for Lexaria, highlighting its innovative approach in the drug delivery industry and its potential impact on the global GLP-1 market.

More about Lexaria Bioscience

Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, known for its patented DehydraTECH technology. This technology enhances the oral delivery of active pharmaceutical ingredients, improving bio-absorption and potentially aiding in drug delivery across the blood-brain barrier. The company operates a licensed research laboratory and holds a substantial intellectual property portfolio with 48 patents granted worldwide.

YTD Price Performance: -36.96%

Average Trading Volume: 190,813

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $25.45M

See more insights into LEXX stock on TipRanks’ Stock Analysis page.